Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease

A protein biomarker discovery workflow was applied to plasma samples from patients at different stages of diabetic kidney disease. The proteomics platform produced a panel of significant plasma biomarkers that were statistically scrutinised against the current gold standard tests on an analysis of 5...

Descripción completa

Detalles Bibliográficos
Autores principales: Bringans, Scott D., Ito, Jun, Stoll, Thomas, Winfield, Kaye, Phillips, Michael, Peters, Kirsten, Davis, Wendy A., Davis, Timothy M.E., Lipscombe, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988498/
https://www.ncbi.nlm.nih.gov/pubmed/29900119
http://dx.doi.org/10.1016/j.euprot.2016.12.001
Descripción
Sumario:A protein biomarker discovery workflow was applied to plasma samples from patients at different stages of diabetic kidney disease. The proteomics platform produced a panel of significant plasma biomarkers that were statistically scrutinised against the current gold standard tests on an analysis of 572 patients. Five proteins were significantly associated with diabetic kidney disease defined by albuminuria, renal impairment (eGFR) and chronic kidney disease staging (CKD Stage ≥1, ROC curve of 0.77). The results prove the suitability and efficacy of the process used, and introduce a biomarker panel with the potential to improve diagnosis of diabetic kidney disease.

Ejemplares similares